|
1
|
Johansson SL and Cohen SM: Epidemiology
and etiology of bladder cancer. Semin Surg Oncol. 13:291–298. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Rhijn BW, Burger M, Lotan Y, Solsona
E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and
progression of disease in non-muscle-invasive bladder cancer: From
epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim YH, Kim WT, Jeong P, Ha YS, Kang HW,
Yun SJ, Moon SK, Choi YH, Kim IY and Kim WJ: Novel combination
markers for predicting survival in patients with muscle invasive
bladder cancer: USP18 and DGCR2. J Korean Med Sci. 29:351–356.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brausi M, Witjes JA, Lamm D, Persad R,
Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A: A
review of current guidelines and best practice recommendations for
the management of nonmuscle invasive bladder cancer by the
International Bladder Cancer Group. J Urol. 186:2158–2167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lotan Y, Shariat SF, Schmitz-Dräger BJ,
Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B,
Bassi PF and Grossman HB: Considerations on implementing diagnostic
markers into clinical decision making in bladder cancer. Urol
Oncol. 28:441–448. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitra AP and Cote RJ: Molecular
pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol.
4:251–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Rhijn BW, Zuiverloon TC, Vis AN,
Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA,
Boevé ER, Jöbsis AC, et al: Molecular grade (FGFR3/MIB-1) and EORTC
risk scores are predictive in primary non-muscle-invasive bladder
cancer. Eur Urol. 58:433–441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dalbagni G, Presti J, Fair W, Reuter VA
and Cordon-Cardo C: Genetic alterations in bladder cancer. Lancet.
342:469–471. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng L, Zhang S, MacLennan GT, Williamson
SR, Lopez-Beltran A and Montironi R: Bladder cancer: Translating
molecular genetic insights into clinical practice. Hum Pathol.
42:455–481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iyer G and Milowsky MI: Fibroblast growth
factor receptor-3 in urothelial tumorigenesis. Urol Oncol.
31:303–311. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jebar AH, Hurst CD, Tomlinson DC, Johnston
C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are
mutually exclusive genetic events in urothelial cell carcinoma.
Oncogene. 24:5218–5225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pandith AA, Shah ZA and Siddiqi MA:
Oncogenic role of fibroblast growth factor receptor 3 in
tumorigenesis of urinary bladder cancer. Urol Oncol. 31:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cappellen D, De Oliveira C, Ricol D, de
Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and
Radvanyi F: Frequent activating mutations of FGFR3 in human bladder
and cervix carcinomas. Nat Genet. 23:18–20. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shiang R, Thompson LM, Zhu YZ, Church DM,
Fielder TJ, Bocian M, Winokur ST and Wasmuth JJ: Mutations in the
transmembrane domain of FGFR3 cause the most common genetic form of
dwarfism, achondroplasia. Cell. 78:335–342. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kompier LC, Lurkin I, van der Aa MN, van
Rhijn BW, van der Kwast TH and Zwarthoff EC: FGFR3, HRAS, KRAS,
NRAS and PIK3CA mutations in bladder cancer and their potential as
biomarkers for surveillance and therapy. PLoS One. 5:e138212010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Juanpere N, Agell L, Lorenzo M, de Muga S,
López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta
J and Hernández S: Mutations in FGFR3 and PIK3CA, singly or
combined with RAS and AKT1, are associated with AKT but not with
MAPK pathway activation in urothelial bladder cancer. Hum Pathol.
43:1573–1582. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hernández S, López-Knowles E, Lloreta J,
Kogevinas M, Jaramillo R, Amorós A, Tardón A, García-Closas R,
Serra C, Carrato A, et al: FGFR3 and Tp53 mutations in T1G3
transitional bladder carcinomas: Independent distribution and lack
of association with prognosis. Clin Cancer Res. 11:5444–5450. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Rhijn BW, Lurkin I, Radvanyi F,
Kirkels WJ, van der Kwast TH and Zwarthoff EC: The fibroblast
growth factor receptor 3 (FGFR3) mutation is a strong indicator of
superficial bladder cancer with low recurrence rate. Cancer Res.
61:1265–1268. 2001.PubMed/NCBI
|
|
20
|
Neuzillet Y, van Rhijn BW, Prigoda NL,
Bapat B, Liu L, Bostrom PJ, Fleshner NE, Gallie BL, Zlotta AR,
Jewett MA and van der Kwast TH: FGFR3 mutations, but not FGFR3
expression and FGFR3 copy-number variations, are associated with
favourable non-muscle invasive bladder cancer. Virchows Arch.
465:207–213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tomlinson DC, Baldo O, Harnden P and
Knowles MA: FGFR3 protein expression and its relationship to
mutation status and prognostic variables in bladder cancer. J
Pathol. 213:91–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hernández S, López-Knowles E, Lloreta J,
Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N and
Real FX: Prospective study of FGFR3 mutations as a prognostic
factor in nonmuscle invasive urothelial bladder carcinomas. J Clin
Oncol. 24:3664–3671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van Rhijn BW, van der Kwast TH, Liu L,
Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett
MA, Zwarthoff EC, et al: The FGFR3 mutation is related to favorable
pT1 bladder cancer. J Urol. 187:310–314. 2012.PubMed/NCBI
|
|
24
|
Torloni H: Histologic typing of urinary
bladder tumors, international histological classification of
tumors. World Health Organization; Geneva: 1973
|
|
25
|
van Oers JM, Lurkin I, van Exsel AJ,
Nijsen Y, van Rhijn BW, van der Aa MN and Zwarthoff EC: A simple
and fast method for the simultaneous detection of nine fibroblast
growth factor receptor 3 mutations in bladder cancer and voided
urine. Clin Cancer Res. 11:7743–7748. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bernard-Pierrot I, Brams A, Dunois-Lardé
C, Caillault A, de Diez Medina SG, Cappellen D, Graff G, Thiery JP,
Chopin D, Ricol D and Radvanyi F: Oncogenic properties of the
mutated forms of fibroblast growth factor receptor 3b.
Carcinogenesis. 27:740–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guancial EA, Werner L, Bellmunt J, Bamias
A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS,
et al: FGFR3 expression in primary and metastatic urothelial
carcinoma of the bladder. Cancer Med. 3:835–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Billerey C, Chopin D, Aubriot-Lorton MH,
Ricol D, Gil Diez, de Medina S, Van Rhijn B, Bralet MP,
Lefrere-Belda MA, Lahaye JB, Abbou CC, et al: Frequent FGFR3
mutations in papillary non-invasive bladder (pTa) tumors. Am J
Pathol. 158:1955–1959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burger M, van der Aa MN, van Oers JM,
Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ,
Denzinger S, Wild PJ, et al: Prediction of progression of
non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and
by FGFR3 mutation status: A prospective study. Eur Urol.
54:835–844. 2008. View Article : Google Scholar : PubMed/NCBI
|
